Page 202 - Drug Class Review
P. 202
Page 131 of 205
Drug Effectiveness Review Project
To evaluate the efficiency of donepezil treatment in early stage Alzheimer’s Disease
placebo N/A 24 weeks 57 Generally healthy ambulatory patients aged 50-92 years; diagnosis of probable AD within the past 12 months; modified Hachinski Ischemia Scale score of 4 or less; Global Dementia Rating score of 0.5 or 1.0; MMSE score of 21-26; mild impairment in activities of daily living If memory decline was possibly attributable to a psychiatric or neurologic disorder or to cognitive deficits following head trauma; previous treatment with cholinesterase inhibitors
Alzheimer Drugs Authors: Seltzer et al. 46 Year: 2004 Country: US Eisai Inc. and Pfizer Inc. Study design: RCT Setting: Multi-center (17 sites) Sample size: 153 donepezil 5-10 mg/d 24 weeks 96 NR
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
